Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–405.

Article  PubMed  CAS  Google Scholar 

Czader M, Orazi A. Therapy-related myeloid neoplasms. Am J Clin Pathol. 2009;132(3):410–25.

Article  PubMed  CAS  Google Scholar 

Hulegardh E, Nilsson C, Lazarevic V, et al. Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish Acute Leukemia Registry. Am J Hematol. 2015;90(3):208–14.

Article  PubMed  Google Scholar 

Dohner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345–77.

Article  PubMed  Google Scholar 

Granfeldt Østgård LS, Medeiros BC, Sengeløv H, et al. Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a National Population-Based Cohort Study. J Clin Oncol. 2015;33(31):3641–9.

Article  PubMed  Google Scholar 

Kayser S, Döhner K, Krauter J, et al. The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood. 2011;117(7):2137–45.

Article  PubMed  CAS  Google Scholar 

Nilsson C, Linde F, Hulegårdh E, et al. Characterization of therapy-related acute myeloid leukemia: increasing incidence and prognostic implications. Haematologica. 2023;108(4):1015–25.

Article  PubMed  CAS  Google Scholar 

Martínez-Cuadrón D, Megías-Vericat JE, Serrano J, et al. Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study. Blood Adv. 2022;6(4):1278–95.

Article  PubMed  PubMed Central  Google Scholar 

Belhabri A, Heiblig M, Morisset S, et al. Clinical outcome of therapy-related acute myeloid leukemia patients. Real-life experience in a University Hospital and a Cancer Center in France. Cancer Med. 2023;12(16):16929–44.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Chen Y, Estrov Z, Pierce S, et al. Myeloid neoplasms after breast cancer: “therapy-related” not an independent poor prognostic factor. Leuk Lymphoma. 2015;56(4):1012–9.

Article  PubMed  CAS  Google Scholar 

Strickland SA, Vey N. Diagnosis and treatment of therapy-related acute myeloid leukemia. Crit Rev Oncol Hematol. 2022;171:103607.

Article  PubMed  Google Scholar 

Araie H, Arai Y, Kida M, et al. Poor outcome of allogeneic transplantation for therapy-related acute myeloid leukemia induced by prior chemoradiotherapy. Ann Hematol. 2023;102(10):2879–93.

Article  PubMed  PubMed Central  CAS  Google Scholar 

DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617–29.

Article  PubMed  CAS  Google Scholar 

Wei AH, Montesinos P, Ivanov V, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood. 2020;135(24):2137–45.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Bouchla A, Papageorgiou SG, Symeonidis A, et al. Evaluation of complete response to azacitidine according to the revised International Working Group 2023 response criteria for higher risk MDS. Does it make a difference in patients’ outcome? Leukemia. 2023;37(12):2517–9.

Article  PubMed  PubMed Central  Google Scholar 

Lee CJ, Labopin M, Beelen D, et al. Comparative outcomes of myeloablative and reduced-intensity conditioning allogeneic hematopoietic cell transplantation for therapy-related acute myeloid leukemia with prior solid tumor: a report from the acute leukemia working party of the European society for blood and bone marrow transplantation. Am J Hematol. 2019;94(4):431–8.

Article  PubMed  CAS  Google Scholar 

Gatwood KS, Labopin M, Savani BN, et al. Transplant outcomes for patients with therapy-related acute myeloid leukemia with prior lymphoid malignancy: an ALWP of EBMT study. Bone Marrow Transplant. 2020;55(1):224–32.

Article  PubMed  CAS  Google Scholar 

Metheny L, Callander NS, Hall AC, et al. Allogeneic transplantation to treat therapy-related myelodysplastic syndrome and acute myelogenous leukemia in adults. Transplant Cell Ther. 2021;27(11):923.e1-923.e12.

Article  PubMed  CAS  Google Scholar 

Godley LA, Larson RA. Therapy-related myeloid leukemia. Semin Oncol. 2008;35(4):418–29.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Offman J, Opelz G, Doehler B, et al. Defective DNA mismatch repair in acute myeloid leukemia/myelodysplastic syndrome after organ transplantation. Blood. 2004;104(3):822–8.

Article  PubMed  CAS  Google Scholar 

Lindsley RC, Mar BG, Mazzola E, et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood. 2015;125(9):1367–76.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Cantu MD, Kanagal-Shamanna R, Wang SA, et al. Clinicopathologic and molecular analysis of normal karyotype therapy-related and de novo acute myeloid leukemia: a multi-institutional study by the bone marrow pathology group. JCO Precis Oncol. 2023;7:e2200400.

Article  PubMed  Google Scholar 

Takahashi K, Wang F, Kantarjian H, et al. Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study. Lancet Oncol. 2017;18(1):100–11.

Article  PubMed  Google Scholar 

Shah MV, Chhetri R, Dholakia R, et al. Outcomes following venetoclax-based treatment in therapy-related myeloid neoplasms. Am J Hematol. 2022;97(8):1013–22.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Todisco E, Papayannidis C, Fracchiolla N, et al. AVALON: the Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia. Cancer. 2023;129(7):992–1004.

Article  PubMed  Google Scholar 

DiNardo CD, Maiti A, Rausch CR, et al. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol. 2020;7(10):e724–36.

Article  PubMed  PubMed Central  Google Scholar 

Wei AH, Strickland SA Jr, Hou JZ, et al. Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib/II study. J Clin Oncol. 2019;37(15):1277–84.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Xie J, Bao X, Xue SL, et al. Venetoclax with decitabine as frontline treatment in younger adults with newly diagnosed ELN adverse-risk AML. Blood. 2023;142(15):1323–7.

Article  PubMed  CAS  Google Scholar 

Lu J, Xue SL, Wang Y, et al. Venetoclax and decitabine vs intensive chemotherapy as induction for young patients with newly diagnosed AML. Blood. 2025;145(22):2645–55.

Article  PubMed  CAS  Google Scholar 

DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133(1):7–17.

Article  PubMed  PubMed Central  CAS  Google Scholar